Unilateral or bilateral irradiation in cervical lymph node metastases of unknown primary? A retrospective cohort study.


Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
04 2019
Historique:
received: 17 02 2018
revised: 02 01 2019
accepted: 06 01 2019
pubmed: 4 3 2019
medline: 27 5 2020
entrez: 4 3 2019
Statut: ppublish

Résumé

Patients with cervical lymphadenopathy of unknown primary carcinoma (CUP) usually undergo neck dissection and irradiation. There is an ongoing controversy regarding the extent of nodal and mucosal volumes to be irradiated. We assessed outcomes after bilateral or unilateral nodal irradiation. This retrospective multicentre study included patients with CUP and squamous cellular carcinoma who underwent radiotherapy (RT) between 2000 and 2015. Of 350 patients, 74.5% had unilateral disease and 25.5% had bilateral disease. Of 297 patients with available data on disease and irradiation sides, 61 (20.5%) patients had unilateral disease and unilateral irradiation, 155 (52.2%), unilateral disease and bilateral irradiation and 81 (27.3%), bilateral disease and bilateral irradiation. Thirty-four (9.7%) and 217 (62.0%) patients received neoadjuvant and/or concomitant chemotherapy, respectively. Median follow-up was 37 months. Three-year local, regional, locoregional failure rates and CUP-specific survival were 5.6%, 11.7%, 15.0% and 84.7%, respectively. In patients with unilateral disease, the 3-year cumulative incidence of regional/local relapse was 7.7%/4.3% after bilateral irradiation versus 16.9%/11.1% after unilateral irradiation (hazard ratio = 0.56/0.61, p = 0.17/0.32). The cumulative incidence of CUP-specific deaths was 9.2% after bilateral irradiation and 15.5% after unilateral irradiation (p = 0.92). In multivariate analysis, mucosal irradiation was associated with better local control, whereas no neck dissection, ≥N2b and interruption of RT for more than 4 days were associated with poorer regional control. Toxicity was higher after bilateral irradiation (p < 0.05). No positron-emission tomography-computed tomography, largest node diameter, ≥N2b, neoadjuvant chemotherapy and interruption of RT were associated with poorer cause-specific survival. Bilateral nodal irradiation yielded non-significant better nodal and mucosal control rates but was associated with higher rates of severe toxicity.

Identifiants

pubmed: 30826659
pii: S0959-8049(19)30016-4
doi: 10.1016/j.ejca.2019.01.004
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

69-81

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Carole Pflumio (C)

Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.

Idriss Troussier (I)

Department of Radiation Therapy, CHU Pitié Salpêtrière, Assistance Publique, Hôpitaux de Paris, Paris, France.

Xu Shan Sun (XS)

Department of Radiation Therapy, Hôpital de Montbéliard, Montbéliard, France.

Julia Salleron (J)

Department of Biostatistics and Data Management, Institut de Cancérologie de Lorraine, Vandoeuvre-Lès-Nancy, France.

Claire Petit (C)

Department of Radiation Therapy, Institut Gustave Roussy, Villejuif, France.

Matthieu Caubet (M)

Department of Radiation Therapy, CHU de Besançon, Besançon, France.

Arnaud Beddok (A)

Department of Radiation Therapy, Institut Curie, Paris, France.

Valentin Calugaru (V)

Department of Radiation Therapy, Institut Curie, Paris, France.

Stéphanie Servagi-Vernat (S)

Department of Radiation Therapy, Institut Jean Godinot, Reims, France.

Joël Castelli (J)

Department of Radiation Therapy, Institut Eugène Marquis, Rennes, France.

Jessica Miroir (J)

Department of Radiation Therapy, Institut Jean Perrin, Clermont-Ferrand, France.

Marco Krengli (M)

Department of Radiation Therapy, University of Piemonte Orientale, Pavia, Italy.

Paul Giraud (P)

Department of Radiation Therapy, Hôpital Tenon, Assistance Publique, Hôpitaux de Paris, Paris, France.

Edouard Romano (E)

Department of Radiation Therapy, Hôpital Tenon, Assistance Publique, Hôpitaux de Paris, Paris, France.

Jonathan Khalifa (J)

Department of Radiation Therapy, Institut Universitaire du Cancer, Toulouse, France.

Mélanie Doré (M)

Department of Radiation Therapy, Institut de Cancérologie de l'Ouest, Nantes, France.

Nicolas Blanchard (N)

Department of Radiation Therapy, Clinique les Dentellières, Valenciennes, France.

Alexandre Coutte (A)

Department of Radiation Therapy, CHU d'Amiens, Amiens, France.

Charles Dupin (C)

Department of Radiation Therapy, Centre Antoine Lacassagne, Nice, France.

Shakeel Sumodhee (S)

Department of Radiation Therapy, Centre Antoine Lacassagne, Nice, France.

Yoann Pointreau (Y)

Department of Radiation Therapy, Clinique Victor Hugo, Le Mans, France.

Samir Patel (S)

Department of Radiation Therapy, Mayo Clinic, Arizona, USA.

Amel Rehailia-Blanchard (A)

Department of Radiation Therapy, CHU de Saint-Étienne, Saint-Étienne, France.

Ludivine Catteau (L)

Department of Radiation Therapy, CHU de Poitiers, Poitiers, France.

René-Jean Bensadoun (RJ)

Department of Radiation Therapy, Centre de Haute Énergie, Nice, France.

Yungan Tao (Y)

Department of Radiation Therapy, Institut Gustave Roussy, Villejuif, France.

Vincent Roth (V)

Easy CRF. 8 rue Lecourtois, Mathieu, France.

Lionnel Geoffrois (L)

Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.

Jean-Christophe Faivre (JC)

Academic Department of Radiation Therapy, Lorraine Institute of Cancerology, Vandoeuvre-lès-Nancy, France.

Juliette Thariat (J)

Department of Radiation Therapy, Centre Francois Baclesse, Advanced Resource Center for Hadrontherapy in Europe, Caen, France, Unicaen-Normandie Universite. Electronic address: jthariat@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH